Amarin Co. plc to Post FY2018 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (AMRN)

Share on StockTwits

Amarin Co. plc (NASDAQ:AMRN) – Analysts at Cantor Fitzgerald decreased their FY2018 earnings estimates for shares of Amarin in a report issued on Monday, January 7th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of ($0.35) for the year, down from their previous estimate of ($0.33). Cantor Fitzgerald currently has a “Buy” rating and a $35.00 target price on the stock. Cantor Fitzgerald also issued estimates for Amarin’s FY2019 earnings at ($0.18) EPS.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $55.00 million for the quarter, compared to analysts’ expectations of $60.63 million. The business’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) EPS.

Several other brokerages have also recently commented on AMRN. BidaskClub raised shares of Amarin from a “hold” rating to a “buy” rating in a research report on Tuesday, November 27th. SunTrust Banks reissued a “buy” rating on shares of Amarin in a research report on Monday, January 7th. ValuEngine raised shares of Amarin from a “buy” rating to a “strong-buy” rating in a research report on Monday, September 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target (up previously from $10.00) on shares of Amarin in a research report on Tuesday, September 25th. Finally, Citigroup decreased their price target on shares of Amarin to $20.00 in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Amarin currently has a consensus rating of “Buy” and a consensus price target of $33.20.

NASDAQ:AMRN opened at $18.00 on Thursday. The company has a market cap of $4.85 billion, a P/E ratio of -72.00 and a beta of 1.11. Amarin has a fifty-two week low of $2.35 and a fifty-two week high of $23.33.

Institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP grew its holdings in Amarin by 66.3% in the 2nd quarter. GSA Capital Partners LLP now owns 162,800 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 64,900 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Amarin by 1.4% during the 2nd quarter. BlackRock Inc. now owns 3,392,430 shares of the biopharmaceutical company’s stock worth $10,482,000 after purchasing an additional 46,957 shares in the last quarter. FMR LLC grew its holdings in shares of Amarin by 57.7% during the 2nd quarter. FMR LLC now owns 5,335,221 shares of the biopharmaceutical company’s stock worth $16,486,000 after purchasing an additional 1,952,118 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Amarin by 20.9% during the 2nd quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 19,590 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D acquired a new stake in shares of Amarin during the 3rd quarter worth $3,254,000. Institutional investors and hedge funds own 42.94% of the company’s stock.

In other news, insider John F. Thero sold 607,611 shares of the firm’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $19.07, for a total value of $11,587,141.77. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Joseph T. Kennedy sold 3,173 shares of the firm’s stock in a transaction on Friday, January 11th. The shares were sold at an average price of $18.92, for a total transaction of $60,033.16. The disclosure for this sale can be found here. Insiders sold a total of 1,602,381 shares of company stock worth $26,155,699 over the last 90 days. Company insiders own 4.08% of the company’s stock.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: What is a put option?

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Biocept  Shares Gap Down to $1.67
Biocept Shares Gap Down to $1.67
VirnetX  Shares Gap Up to $6.33
VirnetX Shares Gap Up to $6.33
Zacks: Brokerages Anticipate Repligen Co.  Will Post Quarterly Sales of $50.33 Million
Zacks: Brokerages Anticipate Repligen Co. Will Post Quarterly Sales of $50.33 Million
Stealth 24-Hour Volume Tops $138.00
Stealth 24-Hour Volume Tops $138.00
Molecular Future  1-Day Volume Tops $421,889.00
Molecular Future 1-Day Volume Tops $421,889.00
Deutsche Lufthansa AG  Receives Consensus Recommendation of “Hold” from Brokerages
Deutsche Lufthansa AG Receives Consensus Recommendation of “Hold” from Brokerages


Leave a Reply

© 2006-2019 Ticker Report